U.S. flag

An official website of the United States government

NM_000546.6(TP53):c.871A>G (p.Lys291Glu) AND Hereditary cancer-predisposing syndrome

Germline classification:
Uncertain significance (2 submissions)
Last evaluated:
Jun 6, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000575139.7

Allele description [Variation Report for NM_000546.6(TP53):c.871A>G (p.Lys291Glu)]

NM_000546.6(TP53):c.871A>G (p.Lys291Glu)

Gene:
TP53:tumor protein p53 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17p13.1
Genomic location:
Preferred name:
NM_000546.6(TP53):c.871A>G (p.Lys291Glu)
HGVS:
  • NC_000017.11:g.7673749T>C
  • NG_017013.2:g.18802A>G
  • NM_000546.6:c.871A>GMANE SELECT
  • NM_001126112.3:c.871A>G
  • NM_001126113.3:c.871A>G
  • NM_001126114.3:c.871A>G
  • NM_001126115.2:c.475A>G
  • NM_001126116.2:c.475A>G
  • NM_001126117.2:c.475A>G
  • NM_001126118.2:c.754A>G
  • NM_001276695.3:c.754A>G
  • NM_001276696.3:c.754A>G
  • NM_001276697.3:c.394A>G
  • NM_001276698.3:c.394A>G
  • NM_001276699.3:c.394A>G
  • NM_001276760.3:c.754A>G
  • NM_001276761.3:c.754A>G
  • NP_000537.3:p.Lys291Glu
  • NP_000537.3:p.Lys291Glu
  • NP_001119584.1:p.Lys291Glu
  • NP_001119585.1:p.Lys291Glu
  • NP_001119586.1:p.Lys291Glu
  • NP_001119587.1:p.Lys159Glu
  • NP_001119588.1:p.Lys159Glu
  • NP_001119589.1:p.Lys159Glu
  • NP_001119590.1:p.Lys252Glu
  • NP_001263624.1:p.Lys252Glu
  • NP_001263625.1:p.Lys252Glu
  • NP_001263626.1:p.Lys132Glu
  • NP_001263627.1:p.Lys132Glu
  • NP_001263628.1:p.Lys132Glu
  • NP_001263689.1:p.Lys252Glu
  • NP_001263690.1:p.Lys252Glu
  • LRG_321t1:c.871A>G
  • LRG_321:g.18802A>G
  • LRG_321p1:p.Lys291Glu
  • NC_000017.10:g.7577067T>C
  • NM_000546.4:c.871A>G
  • NM_000546.5:c.871A>G
Protein change:
K132E
Links:
dbSNP: rs1555525126
NCBI 1000 Genomes Browser:
rs1555525126
Molecular consequence:
  • NM_000546.6:c.871A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126112.3:c.871A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126113.3:c.871A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126114.3:c.871A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126115.2:c.475A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126116.2:c.475A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126117.2:c.475A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126118.2:c.754A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276695.3:c.754A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276696.3:c.754A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276697.3:c.394A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276698.3:c.394A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276699.3:c.394A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276760.3:c.754A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276761.3:c.754A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000664928Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Uncertain significance
(Jun 6, 2023)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Citation Link,

SCV002581987Genome-Nilou Lab
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Jun 18, 2022)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenonot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9. Epub 2003 Jun 25.

PubMed [citation]
PMID:
12826609
PMCID:
PMC166245

A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.

Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, Hopf TA, Marks DS, Oren M, Segal E.

Mol Cell. 2018 Jul 5;71(1):178-190.e8. doi: 10.1016/j.molcel.2018.06.012. Erratum in: Mol Cell. 2018 Sep 6;71(5):873. doi: 10.1016/j.molcel.2018.08.013.

PubMed [citation]
PMID:
29979965
See all PubMed Citations (4)

Details of each submission

From Ambry Genetics, SCV000664928.6

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

The p.K291E variant (also known as c.871A>G), located in coding exon 7 of the TP53 gene, results from an A to G substitution at nucleotide position 871. The lysine at codon 291 is replaced by glutamic acid, an amino acid with similar properties. This variant is in the DNA binding domain of the TP53 protein, was not found to have an effect on transactivation capacity, but is predicted to affect several p53 isoforms (IARC TP53 database; Kato S et al. Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8424-9). In addition, this variant was shown to induce apoptosis at rates higher than wild-type, however there was no evidence that this alteration had an effect on the protein's ability to transactivate TP53 target genes (Kakudo Y et al. Cancer Res. 2005 Mar 15;65(6):2108-14). Studies conducted in human cell lines indicate this alteration is proficient at growth suppression and has no dominant negative effect (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). This amino acid position is well conserved in available vertebrate species; however, glutamic acid is the reference amino acid in other vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Genome-Nilou Lab, SCV002581987.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenonot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024